Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.64 |
| ▸ | KISS1R | Q969F8 | 7/20 | 0.61 |
| ▸ | GLP1R | P43220 | 1/20 | 0.59 |
| ▸ | GCGR | P47871 | 1/20 | 0.59 |
| ▸ | GIPR | P48546 | 1/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540457 | 0.92 | GLP1R (0.63) | IL23RKISS1RGLP1RGCGRGIPR | |
| SCHEMBL34467247 | 0.91 | IL23R (0.64) | IL23RKISS1R | |
| SCHEMBL30299216 | 0.90 | GLP1R (0.65) | IL23RKISS1RGLP1RGCGRGIPR | |
| SCHEMBL30712879 | 0.89 | GLP1R (0.62) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL11596073 | 0.88 | IL23R (0.66) | IL23R | |
| SCHEMBL11490971 | 0.88 | IL23R (0.66) | IL23R | |
| SCHEMBL11596064 | 0.88 | IL23R (0.66) | IL23R | |
| SCHEMBL11420342 | 0.88 | IL23R (0.66) | IL23R | |
| SCHEMBL11420357 | 0.88 | IL23R (0.66) | IL23R | |
| SCHEMBL11490981 | 0.88 | IL23R (0.66) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | IL23R 3167/4885KISS1R 193/4885GLP1R 3/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | IL23R 3167/4885KISS1R 193/4885GLP1R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.